DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/46zcvr/recurrent_head) has announced the addition of the "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013" report to their offering.
'Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma.
This research is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team.
Scope
- A snapshot of the global therapeutic scenario for Recurrent Head And Neck Cancer Squamous Cell Carcinoma.
- A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
-
Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma
pipeline on the basis of route of administration and molecule type.
Key Topics Covered:
List of Tables
List of Figures
Introduction
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Overview
Therapeutics Development
An Overview of Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Development by Companies
Companies Involved in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Development
Drug Profiles
- dacomitinib
- (amphinex + bleomycin sulfate)
- futuximab
- PX-866
- panitumumab
- VTX-2337
- AT-101
- RG-7597
- cetuximab biosimilar
Featured News & Press Releases
Appendix
Companies Mentioned
- Amgen
- Ascenta Therapeutics
- Genentech
- Merck KGaA
- Oncothyreon
- PCI Biotech
- Pfizer
- VentiRx Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/46zcvr/recurrent_head
